About Rituxirel 100mg Injection
Rituxirel 100mg Injection contains Rituximab, a targeted monoclonal antibody therapy that belongs to the anti-CD20 class of medications. It is used to treat a variety of cancers and autoimmune disorders, including non-Hodgkins lymphoma, chronic lymphocytic leukemia (CLL), moderate-to-severe rheumatoid arthritis in combination with methotrexate, granulomatosis with polyangiitis, microscopic polyangiitis, and moderate-to-severe pemphigus vulgaris. Rituximab works by targeting CD20 proteins on specific B-lymphocytes, helping to eliminate abnormal or overactive immune cells that contribute to these conditions. Rituxirel 100mg Injection should not be used by individuals who are allergic to Rituximab or any of its ingredients, have severe active infections, or have a significantly weakened immune system. Before beginning treatment, patients should inform their healthcare provider about any history of heart disease, heart failure, breathing disorders, or previous hepatitis B infection, as hepatitis B may reactivate during therapy and lead to serious complications. Pregnancy and breastfeeding are generally not recommended while receiving this medication, and women of childbearing potential should use effective contraception during treatment and for 12 months after the last dose. Common side effects may include infections, low red blood cell counts, dizziness, swelling of the face or body, itchy skin, diarrhea, increased sweating, and changes in blood pressure. Serious infusion-related reactions can occur during or within 24 hours after administration, and patients should seek immediate medical attention if they experience symptoms such as chest pain, breathing difficulties, severe skin reactions, vomiting, headache, throat swelling, or sudden blood pressure changes. Regular monitoring throughout treatment helps ensure the safe and effective use of Rituxirel 100mg Injection.
Advanced Treatment for Non-Hodgkin's LymphomaRituxirel 100mg Injection is indicated for patients diagnosed with Non-Hodgkin's Lymphoma. By targeting and destroying specific cancer cells, this medication offers an advanced therapeutic approach, improving outcomes and progression-free survival rates for individuals combating NHL.
Proper Storage and Handling GuidelinesTo ensure its efficacy and safety, Rituxirel 100mg Injection should always be stored in a refrigerator, maintaining a temperature between 2C and 8C. Avoid freezing the vial, and protect it from direct light until the moment of use. Storing the medicine correctly preserves its stability until the expiration date.
Trusted Indian Export and Supply NetworkManufactured in India, Rituxirel 100mg Injection is available internationally through verified exporters, suppliers, and traders. This robust distribution channel guarantees that healthcare providers and patients receive genuine, high-quality medicines with reliable sourcing and clear traceability.
FAQ's of Rituxirel 100mg Injection:
Q: How is Rituxirel 100mg Injection administered for Non-Hodgkin's Lymphoma?
A: Rituxirel 100mg Injection is administered intravenously by a healthcare professional in a clinical setting. The dosage and frequency depend on the patient's specific treatment plan and medical condition.
Q: What are the primary benefits of using Rituxirel 100mg Injection in NHL treatment?
A: Rituxirel 100mg Injection targets and destroys cancerous B-cells, making it effective in managing Non-Hodgkin's Lymphoma. Its selective action helps in reducing tumor burden and improving patient survival outcomes.
Q: When should Rituxirel 100mg Injection be stored in the refrigerator?
A: Rituxirel 100mg Injection should be refrigerated immediately upon receipt and kept at a temperature between 2C and 8C, ensuring it remains effective until the expiration date in 2028.
Q: Where is Rituxirel 100mg Injection manufactured and exported from?
A: This medicine is manufactured in India and distributed globally by authorized exporters, suppliers, and traders, ensuring availability and compliance with medical standards.
Q: What is the process for receiving Rituxirel 100mg Injection as a patient?
A: A patient diagnosed with Non-Hodgkin's Lymphoma will receive Rituxirel via intravenous infusion in a healthcare facility, administered by qualified professionals according to a prescribed schedule.
Q: What is the active molecular formula and salt composition in Rituxirel 100mg Injection?
A: The injection contains rituximab as its active ingredient and salt composition, specifically formulated for treating Non-Hodgkin's Lymphoma.